Free Trial
LON:AGY

Allergy Therapeutics (AGY) Share Price, News & Analysis

Allergy Therapeutics logo
GBX 7.50 +0.35 (+4.90%)
As of 05/23/2025 11:49 AM Eastern

About Allergy Therapeutics Stock (LON:AGY)

Key Stats

Today's Range
7.08
7.85
50-Day Range
5.40
7.50
52-Week Range
3.43
8
Volume
251,265 shs
Average Volume
436,236 shs
Market Capitalization
£368.63 million
P/E Ratio
N/A
Dividend Yield
8.33%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGY Stock News Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Allergy Therapeutics Seeks Approval for Grass Allergy Treatment
Allergy Therapeutics Unveils Incentive Plans and Share Repurchase
Allergy Therapeutics Shows Financial Turnaround and Clinical Progress
Allergy Therapeutics Sees Growth and Strategic Advances
See More Headlines

AGY Stock Analysis - Frequently Asked Questions

Allergy Therapeutics' stock was trading at GBX 6.53 at the beginning of the year. Since then, AGY shares have increased by 14.9% and is now trading at GBX 7.50.
View the best growth stocks for 2025 here
.

Allergy Therapeutics plc (LON:AGY) issued its quarterly earnings results on Monday, March, 31st. The company reported ($0.23) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative net margin of 72.86% and a negative trailing twelve-month return on equity of 266.59%.

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), genedrive (GDR), Intel (INTC), IQE (IQE), AstraZeneca (AZN) and Babcock International Group (BAB).

Company Calendar

Last Earnings
3/31/2025
Today
5/25/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
LON:AGY
CIK
N/A
Fax
N/A
Employees
612
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-30.7
Net Income
£-52,591,209.13
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£72.18 million
Cash Flow
GBX 2.05 per share
Price / Cash Flow
3.66
Book Value
GBX 0.10 per share
Price / Book
76.00

Miscellaneous

Outstanding Shares
4,915,066,273
Free Float
N/A
Market Cap
£368.63 million
Optionable
Not Optionable
Beta
1.40
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (LON:AGY) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners